Oncolytics Biotech Inc. (ONCY)
| Market Cap | 76.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.84M |
| Shares Out | 62.83M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,181 |
| Open | 1.24 |
| Previous Close | 1.21 |
| Day's Range | 1.21 - 1.24 |
| 52-Week Range | 0.80 - 2.28 |
| Beta | 1.76 |
| Analysts | Buy |
| Price Target | 5.60 (+359.02%) |
| Earnings Date | May 3, 2023 |
About ONCY
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ONCY stock is "Buy." The 12-month stock price forecast is $5.6, which is an increase of 359.02% from the latest price.
News
Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium
SAN DIEGO and CALGARY, AB , March 28, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will particip...
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% objective response rate in advanced/metastatic patients P...
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Friday, March 3, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 21, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today a...
New Strong Buy Stocks for January 18th
DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage SAN DIEGO and CALGARY, AB , Dec. 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc.'s (N...
What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?
Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biot...
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
SAN DIEGO and CALGARY, AB , Nov. 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming S...
Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings ...
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
One complete response (CR) and eight partial responses (PR) achieved in thirteen evaluable patients 69% objective response rate (ORR) is nearly three times greater than the average ORR of ~25% reporte...
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials...
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials 1-4 Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-ca...
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Monday, November 7, 2022, at 8:30 a.m. ET SAN DIEGO, Calif.
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB , Sept. 7, 202...
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success crit...
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, August 11, 2022, at 8:30 a.m. ET SAN DIEGO, CA and CALGARY, AB , July 27, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC)...
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET
Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment Data suggest pelareorep synerg...
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB , June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc...
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, Calif. and CALGARY, AB , May 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will pa...
Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep'...
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant incre...
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting
SAN DIEGO, Calif. and CALGARY, AB , May 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract fo...